Cargando…
Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors
Recent studies have demonstrated anxiolytic potential of pharmacological endocannabinoid (eCB) augmentation approaches in a variety of preclinical models. Pharmacological inhibition of endocannabinoid-degrading enzymes, such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), el...
Autores principales: | Bedse, Gaurav, Bluett, Rebecca J., Patrick, Toni A., Romness, Nicole K., Gaulden, Andrew D., Kingsley, Philip J., Plath, Niels, Marnett, Lawrence J., Patel, Sachin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917016/ https://www.ncbi.nlm.nih.gov/pubmed/29695817 http://dx.doi.org/10.1038/s41398-018-0141-7 |
Ejemplares similares
-
Hexafluoroisopropyl Carbamates as Selective MAGL and Dual MAGL/FAAH Inhibitors: Biochemical and Physicochemical Properties
por: Barth, Maximilian, et al.
Publicado: (2022) -
Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases—focusing on FAAH/MAGL inhibitors
por: Ren, Si-yu, et al.
Publicado: (2020) -
Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
por: Della Pietra, Adriana, et al.
Publicado: (2023) -
Distinct Activity of Endocannabinoid-Hydrolyzing Enzymes MAGL and FAAH in Key Regions of Peripheral and Central Nervous System Implicated in Migraine
por: Della Pietra, Adriana, et al.
Publicado: (2021) -
Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation
por: Bluett, R J, et al.
Publicado: (2014)